Comorbidity of Bipolar Disorder in Cluster Headache: Clinical and Research Implications (Netherlands, 2026)

High Prevalence of Bipolar Disorder in Cluster Headache Patients

A 2026 cross-sectional study from the Leiden University Cluster headache neuro-Analysis program (LUCA) found that 6.5% of patients with cluster headache (CH) also met criteria for bipolar disorder (BD), a rate notably higher than in the general population. The study, published on September 22, 2026 (OpenAlex W7214052100), screened 310 CH patients using validated psychiatric instruments and confirmed diagnoses with structured interviews. This elevated comorbidity highlights a significant overlap between these two cyclic disorders, both of which are characterized by disrupted sleep, response to lithium, and increased risk of illicit drug use.

Mechanistic and Familial Overlap: What the Data Show

The Leiden study provides direct evidence of familial aggregation: patients with both cluster headache and bipolar disorder (CH+BD) were significantly more likely to have family members with BD (standardized odds ratio 1.50, 95% CI: 1.15–1.95, p=0.003). Additionally, CH+BD patients were more likely to suffer from chronic forms of cluster headache (odds ratio 3.05, 95% CI: 1.18–7.87, p=0.02) after adjusting for age and sex. While both disorders share circadian features, the study found no significant difference in circadian type or chronotype between CH-only and CH+BD groups after controlling for confounders. Notably, CH+BD patients reported higher rates of illicit drug use, which may reflect attempts at self-medication or increased vulnerability to substance use disorders.

Implications for Psychedelic Research and Clinical Trials

The observed comorbidity has direct implications for psychedelic research, as both cluster headache and bipolar disorder are targets of emerging clinical trials involving substances such as psilocybin and LSD. Patient selection criteria for these trials must account for the higher risk of BD among CH patients, given the potential for psychedelics to trigger manic or psychotic episodes in susceptible individuals. This finding supports systematic psychiatric screening—using structured tools like the Mini International Neuropsychiatric Interview (MINI)—in headache clinics and as part of trial enrollment protocols. Importantly, the study's use of validated Dutch-language instruments (MDQ-NL, ASRM-NL) demonstrates a scalable approach for international research teams seeking to replicate or build upon these findings.

• Concrete example: A non-obvious implication is that trial exclusion criteria based solely on self-reported psychiatric history may miss a significant proportion of CH patients with undiagnosed BD, potentially increasing trial risk profiles.

Risks, Unknowns, and Clinical Cautions

Screening for bipolar disorder is essential in both clinical and research settings for CH patients, as undiagnosed BD can complicate treatment and increase the risk of adverse outcomes, particularly with serotonergic agents or psychedelics. The study did not assess the impact of comorbidity on treatment response or long-term outcomes, and it did not directly address the safety or efficacy of psychedelic interventions. Furthermore, the observed association between comorbidity and illicit drug use raises questions about causality, self-medication, and the potential for substance misuse in this population. As psychedelic trials expand, careful risk stratification and post-trial monitoring will be critical to prevent psychiatric destabilization.

Looking Ahead: Research and Policy Directions

Future research should investigate whether the comorbidity of BD and CH reflects shared neurobiological mechanisms—such as hypothalamic dysfunction or circadian rhythm disruption—that could inform precision medicine approaches. Policymakers and ethics boards overseeing psychedelic trials should consider requiring structured psychiatric assessments and family history evaluations for all CH participants. As the Netherlands and other jurisdictions continue to pilot psychedelic-assisted therapies, this study underscores the need for cross-disciplinary collaboration between headache specialists, psychiatrists, and trialists to ensure patient safety and data integrity. The findings may also prompt insurers and regulators to update guidelines for psychiatric screening in headache clinics, potentially influencing access to both conventional and experimental treatments.

How we research: This article was researched and written by Dr. Alex van Rijn, MD, PhD (neuropsychiatry, Leiden University), and reviewed by Dr. Marieke Jansen, MD (psychiatry, Erasmus MC) on 2026-09-24. Primary source: OpenAlex W7214052100.